Despite decades of research, brain tumours remain among the deadliest of all forms of cancer.
The ability of these tumours to resist almost all conventional and novel treatments relates, …

Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

The ALK F1174L mutation is associated with intrinsic and acquired resistance to crizotinib
and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model …

Captopril, an inhibitor of angiotensin converting enzyme, is widely used clinically to manage
hypertension and congestive heart failure. Here captopril is shown to be an inhibitor of …

In Alzheimer's disease (AD), affected neurons accumulate beta amyloid protein, components
of which can induce mouse microglia to express the high-output isoform of nitric oxide …

Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors,
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by MYCN, …

Matrix proteases play a critical role in cell invasion and migration, including the process of
angiogenesis. The ability of specific factors to induce angiogenic responses correlates with …

Amplification of MYCN occurs commonly in neuroblastoma. We report that phosphatidylinositol
3-kinase (PI3K) inhibition in murine neuroblastoma (driven by a tyrosine hydroxylase-…

The proto-oncogene MYCN is mis-expressed in various types of human brain tumors. To
clarify how developmental and regional differences influence transformation, we transduced …

PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent …